MULTI-PARAMETRIC MRI DETERMINATION OF PROSTATE CANCER AGGRESSIVENESS AND EXTENT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目前的诊断测试不能可靠地确定前列腺癌的范围(体积和位置)或生物侵袭性。本研究的主要目标是通过将解剖和功能研究产生的多参数数据结合在一个新的统计模型中，实现3Tesla MRI生成癌症概率图的全部潜力。这一目标将通过实现以下四个具体目标来实现：1)从用新技术获取和处理的MRI数据生成参数图；2)开发和验证三维(3D)策略，以将MRI图像与前列腺癌切除的组织病理学切片进行空间联合配准；3)开发基于3T MRI数据的分类器，以生成癌症的3D概率图；以及4)识别预测侵袭性的组织学和分子标记的MRI特征。我们期望的结果是开发一种新的基于MRI的成像方法，以非侵入性和可靠的方式确定前列腺癌的范围和侵袭性。我们希望，这项研究中开发的方法可以让医生和他们的患者做出更好的治疗决定，并降低前列腺癌的发病率和死亡率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Current diagnostic tests cannot reliably determine prostate cancer extent (volume and location) or biological aggressiveness. The main goal of this research is to realize the full potential of 3 Tesla MRI to generate cancer probability maps by combining the multi-parametric data generated from anatomic and functional studies within a new statistical model. This goal will be accomplished by realizing the following four specific aims: 1) generate parametric maps from MRI data acquired and processed with novel techniques; 2) develop and validate a 3-dimensional (3D) strategy to spatially co-register MRI images to histopathology sections from prostatectomy; 3) develop a classifier based on 3T MRI data to produce a 3D probability map of cancer; and 4) identify MRI features that predict histological and molecular markers of aggressiveness. Our expected outcome is the development of a novel MRI-based imaging method to non-invasively and reliably determine both the extent and aggressiveness of prostate cancer. It is our hope that the methods developed in this study may permit doctors and their patients to make better treatment decisions and reduce morbidity and mortality due to prostate cancer.